Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991068 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome
A Phase 2 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00991068 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 24 participants.
The verdict
NCT00991068, a Phase 2 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.
Interventions
- DRUG Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00991068
The ClinicalTrials.gov registry entry for NCT00991068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch is the first listed.
NCT00991068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00991068 about?
NCT00991068 is a clinical study titled "Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome". The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.
What is the current status of trial NCT00991068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00991068?
The interventions under investigation include: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch (DRUG).
Who is sponsoring clinical trial NCT00991068?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.